{"id":57826,"date":"2023-07-29T04:01:06","date_gmt":"2023-07-29T02:01:06","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\/"},"modified":"2023-07-29T04:01:06","modified_gmt":"2023-07-29T02:01:06","slug":"navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\/","title":{"rendered":"Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination"},"content":{"rendered":"
\n

DUBLIN, Ohio–(BUSINESS WIRE)–Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (\u201cNavidea\u201d or the \u201cCompany\u201d), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received written notification from NYSE American LLC (“NYSE American” or the “Exchange”) stating that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Navidea Biopharmaceuticals, Inc. (the \u201cCompany\u201d) \u2014 ticker symbol NAVB \u2014from the Exchange. The Company’s Board of Directors has determined to appeal the Exchange’s determination to commence delisting proceedings.<\/p>\n

<\/a>
<\/a><\/p>\n

\nNYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1009(a) of the NYSE American Company Guide (the \u201cCompany Guide\u201d) as the Company was unable to demonstrate that it had regained compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide by the end of the maximum 18-month compliance plan period, which expired on July 28, 2023. The Exchange\u2019s application with the Securities and Exchange Commission to delist the Company\u2019s common stock is pending, subject to completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff\u2019s decision.<\/p>\n

\nThe Company has a right to an appeal of the staff\u2019s determination by the Exchange, provided that the Company files a written request for such review within seven calendar days after receiving the notice. The Company’s Board of Directors has determined to appeal the Exchange’s determination to commence delisting proceedings. There can be no assurance that Navidea\u2019s request for continued listing will be granted.<\/p>\n

\nThe Company\u2019s common stock will continue to be listed and traded on NYSE American during the pendency of the Company\u2019s appeal, subject to NYSE American\u2019s discretion to immediately suspend trading if it believes suspension to be in the public interest, for the protection of investors, or to promote just and equitable principles of trade.<\/p>\n

\nNavidea intends to make arrangements to have its common stock quoted in the over-the-counter market if its common stock is delisted from the Exchange.<\/p>\n

\nAbout Navidea<\/b><\/p>\n

\nNavidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea\u2019s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea\u2019s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company\u2019s pipeline through global partnering and commercialization efforts. For more information, visit www.navidea.com<\/a>.<\/p>\n

\nAbout G2G Ventures<\/b><\/p>\n

\nG2G Ventures <\/b>is a <\/b>Colorado-based private equity firm focused on empowering organizations to reach their full potential through investment and consulting services. Specializing in creating long-term partnerships with trusted investors and established businesses, G2G Ventures draws on strong internal balance sheet liquidity, augmented by trusted investor capital, to craft bespoke capital solutions which include private equity investment, venture capital participation, and mezzanine debt options. Beyond financial investment, G2G Ventures provides accretive consulting services to help clarify strategic goals and key performance indicators (KPIs), evolve financial processes, and enhance operational effectiveness. To learn more about how G2G Ventures is a growth partner for enduring business, connect<\/a> with our team.<\/p>\n

\nForward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our common stock is subject to delisting from the NYSE American under a currently pending delisting proceeding; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at http:\/\/www.sec.gov<\/a> or at http:\/\/ir.navidea.com<\/a>.<\/p>\n

\nInvestors are urged to consider statements that include the words \u201cwill,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cplan,\u201d \u201ccontinue,\u201d \u201cdesigned,\u201d \u201cgoal,\u201d \u201cforecast,\u201d \u201cfuture,\u201d \u201cbelieve,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cproject,\u201d and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.<\/p>\n

\nYou are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Relations Contact<\/b><\/p>\n

Navidea Biopharmaceuticals, Inc.
\n
G2G Ventures – Executive Consultant
\n
Theodore Gerbick
\n
Chief Marketing Officer
\n
tgerbick@g2g.ventures<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

DUBLIN, Ohio–(BUSINESS WIRE)–Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (\u201cNavidea\u201d or the \u201cCompany\u201d), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received written notification from NYSE American LLC (“NYSE American” or the “Exchange”) stating that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Navidea … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-57826","6":"format-standard","7":"category-industry"},"yoast_head":"\nNavidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN, Ohio–(BUSINESS WIRE)–Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (\u201cNavidea\u201d or the \u201cCompany\u201d), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received written notification from NYSE American LLC (“NYSE American” or the “Exchange”) stating that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Navidea ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-29T02:01:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230728368165\/en\/389794\/21\/navidea_cmyk.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination\",\"datePublished\":\"2023-07-29T02:01:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\\\/\"},\"wordCount\":1019,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230728368165\\\/en\\\/389794\\\/21\\\/navidea_cmyk.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\\\/\",\"name\":\"Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230728368165\\\/en\\\/389794\\\/21\\\/navidea_cmyk.jpg\",\"datePublished\":\"2023-07-29T02:01:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230728368165\\\/en\\\/389794\\\/21\\\/navidea_cmyk.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230728368165\\\/en\\\/389794\\\/21\\\/navidea_cmyk.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\/","og_locale":"en_US","og_type":"article","og_title":"Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination - Pharma Trend","og_description":"DUBLIN, Ohio–(BUSINESS WIRE)–Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (\u201cNavidea\u201d or the \u201cCompany\u201d), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received written notification from NYSE American LLC (“NYSE American” or the “Exchange”) stating that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Navidea ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\/","og_site_name":"Pharma Trend","article_published_time":"2023-07-29T02:01:06+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230728368165\/en\/389794\/21\/navidea_cmyk.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination","datePublished":"2023-07-29T02:01:06+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\/"},"wordCount":1019,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230728368165\/en\/389794\/21\/navidea_cmyk.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\/","url":"https:\/\/pharma-trend.com\/en\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\/","name":"Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230728368165\/en\/389794\/21\/navidea_cmyk.jpg","datePublished":"2023-07-29T02:01:06+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230728368165\/en\/389794\/21\/navidea_cmyk.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230728368165\/en\/389794\/21\/navidea_cmyk.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/navidea-biopharmaceuticals-inc-announces-nyse-american-has-commenced-delisting-proceedings-and-intent-to-appeal-nyse-american-determination\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=57826"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57826\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=57826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=57826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=57826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}